MedTrace Logo

Discovery and Validation of Proteogenomic Biomarker Panels in Liver Transplant Recipients

NCT01672164 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 202

Last updated 2016-09-02

No results posted yet for this study

Summary

The main focus of this study is to develop blood and/or urine tests that will help to detect early signs of rejection in people who have had a liver transplant. Researchers will examine blood, urine, and tissue samples and try to identify markers for certain conditions such as rejection, response to therapy, and scarring of the liver. Additionally, researchers would like to identify biomarkers that can detect damage to the native kidneys before blood levels of creatinine rises. By studying gene expression, researchers hope to be able to diagnose these conditions earlier and improve liver survival.

Conditions

  • Liver Transplant Recipients
  • Liver Transplantation

Sponsors & Collaborators

  • Clinical Trials in Organ Transplantation

    collaborator NETWORK

  • National Institute of Allergy and Infectious Diseases (NIAID)

    lead NIH

Principal Investigators

  • Josh Levitsky, MD, MS · Northwestern University Feinberg School of Medicine

  • Michael Abecassis, MD, MBA · Northwestern University Feinberg School of Medicine

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-08-31
Primary Completion
2015-12-31
Completion
2015-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01672164 on ClinicalTrials.gov